Search

Search Constraints

You searched for: Author/Creator Zamora, L.

Search Results

11. SAT0430 Assessment of acr and slicc classification criteria in the asia pacific lupus collaboration cohort. (12th June 2018)

12. Spanish Guidelines for the use of Targeted Deep Sequencing in MDS and CMML. (April 2017)

13. Targeted Deep Sequencing of Peripheral CD34+ Cells can Reproduce Bone Marrow Molecular Profile in MDS Patients. (April 2017)

14. THU0350 Time dependent association of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus. (12th June 2018)

15. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES. (May 2023)

16. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS. (May 2023)

17. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: SINGLE-CELL MULTIOMICS ANALYSIS OF MYELODYSPLASTIC SYNDROME PREDICTS CLINICAL RESPONSE TO DNA METHYLATION INHIBITOR THERAPY. (May 2023)

18. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPACT OF GERIATRIC ASSESSMENT AND SOMATIC MUTATIONS IN HIGH-RISK MYELODYSPLASTIC SYNDROMES NOT ELIGIBLE FOR ALO-HCST. CET-AZA-2016–1 2022 UPDATE. ON BEHALF OF THE CETLAM GROUP. (May 2023)

19. Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS. (May 2023)

20. TP53 Mutations in High Risk Myelodysplastic Syndromes Patients Treated with Azacitidine According to Cetlam Group Protocol. (April 2017)